DSpace Repository

Current Understanding on COVID-19 Vaccines: A mini Review

Show simple item record

dc.contributor.author Nahar, Nadimun
dc.date.accessioned 2022-11-26T05:27:19Z
dc.date.available 2022-11-26T05:27:19Z
dc.date.issued 22-06-30
dc.identifier.uri http://dspace.daffodilvarsity.edu.bd:8080/handle/123456789/9003
dc.description.abstract The COVID-19 sickness is brought on by the novel SARS-CoV-2 virus, an RNA virus that is a member of the Coronaviridae group. The sequence virus seems to have originated in China and easily spread across the globe. The COVID-19 flu epidemic, which is arguably the second most deadly in the last century after the Spanish flu, necessitates a swift assessment of the various techniques are employed' efficacy in inducing resistance mechanisms and security in preventing unintended completely impervious, which is crucial to the pathogenesis of such a virus. In order to lower illness and death, it is therefore imperative that an adequate vaccination against this illness be developed in laboratories all over the globe. There are several technologies for developing vaccines, including virus-vectored vaccines, protein pneumococcal polysaccharide, genomic vaccines, and immunotherapies for vaccines that are being evaluated for SARS-CoV-2. Each of these platforms has certain advantages and disadvantages. Twenty vaccines have received approval from at least one nationwide regulatory body for use in the general population, including two RNA vaccines (Pfizer-BioNTech and Moderna), 9 traditional immobilized vaccines (BBIBP-CorV, Chinese Institute of education of Health Sciences, CoronaVac, Covaxin, CoviVac, COVIran Barakat, Minhai-Kangtai, QazVac, and WIBP-CorV), 5 virus - based vaccines (Sputnik Light, Sput. The WHO has authorized its use of the crisis vaccines produced by Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, Sinopharm, Sinovac, and Janssen. These shots may be given out as a COVAX component. All of the COVID-19 vaccines have demonstrated positive responsiveness, differing degrees of security practitioners, and a manageable low toxicity in clinical studies. Throughout all vaccinations, a stronger immune reaction is produced after the second dosage. Older people perform immunologically even worse younger people. It is need to conduct further study on vaccination regimens, including more regular vaccinations or higher doses each needle. en_US
dc.language.iso en_US en_US
dc.publisher Daffodil International University en_US
dc.subject Virus en_US
dc.subject COVID-19 en_US
dc.subject Flue en_US
dc.title Current Understanding on COVID-19 Vaccines: A mini Review en_US
dc.type Other en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account